406 related articles for article (PubMed ID: 15504124)
1. In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China.
Li RY; Wan Z; Wang AP; Shen YN; Lu CM; Li M; Xi LY; Liu WD; Zeng FQ
Mycoses; 2004 Oct; 47(9-10):402-6. PubMed ID: 15504124
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes.
Tamura T; Asahara M; Yamamoto M; Yamaura M; Matsumura M; Goto K; Rezaei-Matehkolaei A; Mirhendi H; Makimura M; Makimura K
Microbiol Immunol; 2014 Jan; 58(1):1-8. PubMed ID: 24215461
[TBL] [Abstract][Full Text] [Related]
3. [In vitro antifungal activities of amorolfine against fresh isolates from patients with cutaneous mycosis].
Uchida K; Aoki K; Yamaguchi H
Jpn J Antibiot; 1991 Sep; 44(9):1007-12. PubMed ID: 1960850
[TBL] [Abstract][Full Text] [Related]
4. [In vitro action spectrum of a new antifungal agent derived from morpholine: amorolfin].
Regli P; Ferrari H
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):617-20. PubMed ID: 2797885
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of four antifungal drugs against Trichophyton rubrum isolates exhibiting resistance to fluconazole.
Santos DA; Hamdan JS
Mycoses; 2007 Jul; 50(4):286-9. PubMed ID: 17576321
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses.
Koga H; Tsuji Y; Inoue K; Kanai K; Majima T; Kasai T; Uchida K; Yamaguchi H
J Infect Chemother; 2006 Jun; 12(3):163-5. PubMed ID: 16826352
[TBL] [Abstract][Full Text] [Related]
7. [Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
Xu Y; Pang GR; Zhao DQ; Gao CW; Zhou LT; Sun ST; Wang BL; Chen ZJ
Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):38-42. PubMed ID: 20388321
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
Sarifakioglu E; Seçkin D; Demirbilek M; Can F
Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients.
Traboulsi RS; Mukherjee PK; Ghannoum MA
Int J Antimicrob Agents; 2008 Mar; 31(3):272-6. PubMed ID: 18242063
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes.
Ghannoum MA; Welshenbaugh A; Imamura Y; Isham N; Mallefet P; Yamaguchi H
Mycoses; 2010 Jul; 53(4):311-3. PubMed ID: 19422522
[TBL] [Abstract][Full Text] [Related]
11. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
12. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.
Croxtall JD; Plosker GL
Drugs; 2009; 69(3):339-59. PubMed ID: 19275277
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
14. Antifungal activities and cytotoxicity studies of six new azasordarins.
Herreros E; Almela MJ; Lozano S; Gomez de las Heras F; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Nov; 45(11):3132-9. PubMed ID: 11600368
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of griseofulvin against clinical isolates of dermatophytes from Isfahan.
Chadeganipour M; Nilipour S; Havaei A
Mycoses; 2004 Dec; 47(11-12):503-7. PubMed ID: 15601457
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal activities of luliconazole, a new topical imidazole.
Koga H; Nanjoh Y; Makimura K; Tsuboi R
Med Mycol; 2009; 47(6):640-7. PubMed ID: 19115136
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs.
Tatsumi Y; Yokoo M; Arika T; Yamaguchi H
Antimicrob Agents Chemother; 2001 May; 45(5):1493-9. PubMed ID: 11302816
[TBL] [Abstract][Full Text] [Related]
18. Fluorometric assessment of In vitro antidermatophytic activities of antimycotics based on their keratin-penetrating power.
Okeke CN; Tsuboi R; Kawai M; Ogawa H
J Clin Microbiol; 2000 Feb; 38(2):489-91. PubMed ID: 10655333
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait.
Asadzadeh M; Al-Sweih NA; Ahmad S; Khan ZU
Mycoses; 2008 Jul; 51(4):318-23. PubMed ID: 18855844
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial.
Ghannoum MA; Wraith LA; Cai B; Nyirady J; Isham N
Br J Dermatol; 2008 Sep; 159(3):711-3. PubMed ID: 18510668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
